Precursor synthesis towards the development of [124I]‐labelled 2′, 2′‐difluoro‐2′‐deoxycytidine as a potential pet radiotracer for the anticancer drug gemcitabine

Abstract

AbstractThe anticancer nucleoside analogue, Gemcitabine (2′, 2′‐difluoro‐2′‐deoxycytidine) is an active nucleoside against solid tumours. Assessment of tumour and normal tissue concentration of drug in vivo provides pharmacokinetic data that can be related to response to treatment. Towards enabling PET imaging, the synthesis of a halogenated analogue has been undertaken for subsequent radiolabelling with 124I.